Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page now displays revision v3.7.1 instead of v3.7.0. The study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-07T00:26:55.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page instead of the study record content. The new page shows a minimal header with a Home link, indicating restricted access to the record rather than substantive study information.
    Difference
    20%
    Check dated 2026-09-23T00:22:47.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.6.6 to v3.7.0, indicating a newer version of the page template or CMS. No study-related content is altered.
    Difference
    0.0%
    Check dated 2026-09-15T23:50:00.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.6, indicating a small update to the study record without altering displayed content.
    Difference
    0.0%
    Check dated 2026-09-01T20:00:27.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The study record now shows a funding attribution: '2023 ( U.S. NIH Grant/Contract )', indicating NIH support for the trial. This addition updates the record to disclose the study's funding source.
    Difference
    0.0%
    Check dated 2026-08-25T21:41:38.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5 on the page, indicating a new published revision. This reflects a maintenance/version update rather than a substantive change to the page's content.
    Difference
    0.0%
    Check dated 2026-08-11T16:37:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.